Introduction {#S1}
============

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease characterized by hyperglycemia secondary to insulin resistance and pancreatic β-cell failure ([@B2]). The findings of human epidemiologic studies indicate that the global prevalence of T2DM is increasing rapidly, and this increase parallels the increase in the prevalence of obesity ([@B34]). The body mass index (BMI) is routinely used to quantify the overall obesity although body fat distribution of individuals can vary substantially. The waist-to-hip ratio (WHR) and WHR adjusted for BMI (WHRadjBMI) are frequently used surrogate measures of abdominal obesity. Many observational epidemiologic studies, including case--control and cohort studies, have demonstrated that higher WHR and BMI are two important risk factors for developing T2DM ([@B37]; [@B24]). Moreover, cohort and cross-sectional studies ([@B40]; [@B5]) demonstrated that BMI and WHR were associated with glycemic traits, including fasting insulin, Hemoglobin A1c (HbA1c), and insulin resistance \[measured by Homeostatic model assessment of insulin resistance (HOMA-IR)\]. Longitudinal and cross-sectional studies have found an association between increased risk of T2DM and higher genetic predisposition to both BMI and WHRadjBMI in European and East Asian populations ([@B32]; [@B47]; [@B19]).

However, these observational studies cannot avoid the bias induced by the confounding effect and reverse causation and, therefore, are incapable of confirming whether these associations are causal ([@B36]). Mendelian randomization (MR) is an approach that is used to unbiasedly test or estimate the causal relationship between an exposure and an associated outcome by using data on inherited genetic variants that influence exposure status in the presence of unmeasured confounding ([@B12]; [@B22]). In the past few years, MR has been extensively used in epidemiology and other related areas of population science ([@B35]; [@B39]; [@B45]).

Previous MR analyses have demonstrated that per 1 standard deviation (SD) higher WHRadjBMI and BMI were causally associated with T2DM risk in European populations ([@B10]; [@B14]). [@B40] conducted an MR to further investigate the causal effect of both BMI and WHR on glycemic traits, and they found that BMI had a causal relevance for insulin secretion, whereas neither WHR and BMI was causally associated with HOMA-IR in a conventional MR in a Chinese Han population. However, there is a dearth of MR studies for testing and comparing the causal effect of both overall and abdominal obesity on glycemic in the European population. Epidemiologic studies have found differences in T2DM epidemiologic characteristics between the Asian and European population wherein, in comparison with South Asians, Europeans have a lower T2DM risk, typically develop T2DM 5--10 years later, and have a slower disease progression ([@B17]; [@B1]; [@B18]; [@B26]; [@B4]). Moreover, Europeans developed many metabolic abnormalities, including hyperglycemia and elevated triacylglycerol and low high-density lipoprotein cholesterol (HDL-C), at a higher BMI and age ([@B29]; [@B30]). Therefore, the estimation and comparison of the causal effects of overall and abdominal obesity on glycemic traits could provide insights into the obesity-related mechanism of T2DM.

In this study, a two-sample Mendelian randomization (TSMR) with a large sample size was conducted to determine whether a genetic predisposition to increased BMI, WHR, and WHRadjBMI was causally associated with T2DM and glycemic traits, including HOMA-IR, fasting insulin, fasting glucose, and HbA1c. The causal effects were further compared to identify differences in the effect of overall and abdominal obesity on T2DM development and glycemic traits.

Materials and Methods {#S2}
=====================

Data Source {#S2.SS1}
-----------

This study aimed to explore the causal effect of WHR, BMI, and WHRadjBMI on the risk of T2DM and glycemic traits (HOMA-IR, fasting insulin, fasting glucose, and HbA1c) in an European population, and used diastolic blood pressure (DBP), systolic blood pressure (SBP), HDL-C, and low-density lipoprotein cholesterol (LDL-C) as the covariates. The genome-wide association study summary statistics datasets used in this study were obtained from Zenodo^[1](#footnote1){ref-type="fn"}^ for WHR ([@B8]), BMI ([@B8]), and WHRadjBMI ([@B8]); the Program in Complex Trait Genomics^[2](#footnote2){ref-type="fn"}^ for T2DM ([@B44]); MAGIC Consortium^[3](#footnote3){ref-type="fn"}^ for HOMA-IR ([@B13]), fasting glucose ([@B25]), fasting insulin ([@B25]), and HbA1c ([@B42]); the MRBase platform^[4](#footnote4){ref-type="fn"}^ for HDL-C ([@B20]) and LDL-C ([@B20]); and the MRC-IEU Consortium^[5](#footnote5){ref-type="fn"}^ for SBP and DBP. Detailed information of the summary statistics datasets are displayed in [Table 1](#T1){ref-type="table"}. We obtained the β-coefficients and standard errors for the per allele association of each single-nucleotide polymorphism (SNP) as well as all exposures and outcomes from these data sources.

###### 

Summary statistics of data source.

  Traits            Consortium                          Data sources                 No. of participants   No. of Variants   Population   Units in TSMR
  ----------------- ----------------------------------- ---------------------------- --------------------- ----------------- ------------ ---------------
  WHR               ZENODO                              Censin; PloS Genet; 2019     697,734               27,381,301        European     SD
  BMI               ZENODO                              Censin; PloS Genet; 2019     806,834               27,376,273        European     SD
  WHRadjBMI         ZENODO                              Censin; PloS Genet; 2019     694,649               27,375,636        European     SD
  HDL-C             MRBase                              Kettunen; Nat Commun; 2016   21,555                11,865,530        European     SD
  LDL-C             MRBase                              Kettunen; Nat Commun; 2016   21,559                11,871,461        European     SD
  SBP               MRC-IEU                             Ben Elsworth; 2018           436,419               9,851,867         European     SD
  DBP               MRC-IEU                             Ben Elsworth; 2018           436,424               9,851,867         European     SD
  Fasting glucose   MAGIC                               Manning, Nat Genet; 2012     58,074                2,628,880         European     mmol/L
  Fasting insulin   MAGIC                               Manning, Nat Genet; 2012     51,750                2,627,849         European     log pmol/L
  HOMA-IR           MAGIC                               Dupuis; Nat Genet; 2010      37,037                2,458,074         European     log HOMA
  HbA1c             MAGIC                               Wheeler, PloS Med; 2017      123,655               2,586,698         European     \%
  T2DM              Program in Complex Trait Genomics   Xue; Nat Commun; 2018        62,892/596,424        5,053,015         European     log odds

WHR, waist-to-hip ratio; BMI, body mass index; WHRadjBMI, waist-to-hip ratio adjusted for body mass index; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; DBP, diastolic blood pressure; T2DM, Type 2 diabetes; TSMR, two-sample Mendelian randomization; SD, standard deviation; HOMA-IR, Homeostasis model assessment of insulin resistance; HbA1c, Hemoglobin A1c.

Selection of Genetic Instrumental Variables {#S2.SS2}
-------------------------------------------

In the TSMR analysis conducted in this study, the genetic variants for exposures (BMI, WHR, and WHRadjBMI) were used as instrumental variables (IVs) and were obtained by two steps. Firstly, SNPs that are strongly associated with exposures (*P* \< 5.0 × 10^--8^) were extracted. Secondly, we pruned these extracted SNPs by linkage disequilibrium (LD; *r*^2^ = 0.001, clumping distance = 10,000 kb) to ensure that each IV was independent of the others. To test the strength of the IVs, the *F*-statistics were calculated as previously described ([@B43]). *F*-statistics \>10 are considered adequately strong to mitigate against any bias of the causal IV estimate.

Heterogeneity and Horizontal Pleiotropic Analysis {#S2.SS3}
-------------------------------------------------

In MR, heterogeneity in the causal estimate may indicate that a variant has an effect on the outcome outside of its effect on the exposure (known as horizontal pleiotropy), and this can cause severe bias ([@B11]). Mendelian randomization--Egger (MR--Egger) regression was undertaken to assess the horizontal pleiotropy of the IVs, where a regression intercept that significantly differed from zero (*P* \< 0.05) indicated the presence of horizontal pleiotropy exists or that the InSIDE (INstrument Strength Independent of Direct Effect) assumption was violated ([@B7]). Heterogeneity between IVs in the conventional MR, with the inverse-variance weighted (IVW) method, was estimated by *Cochran's Q* statistic. The MR pleiotropy residual sum and outlier (MR--PRESSO) method can be used to test horizontal pleiotropic outliers and can obtain the corrected causal effect after removal of these outliers in MR ([@B38]). In the present study, both MR--Egger regression and MR--PRESSO tests were conducted using the TwoSampleMR and MRPRESSO R package in R (version 3.6.1), respectively.

Mendelian Randomization {#S2.SS4}
-----------------------

Mendelian randomization can test and estimate the causal effect of an exposure on an outcome by using genetic variants as the IVs ([@B46]). Firstly, Wald ratios were calculated for each IV by dividing the per-allele log-odds ratio (or beta) of that variant in the outcome data by the log-odds ratio (or beta) of the same variant in the exposure data. Then, the random-effects IVW method was applied to estimate the association between exposures and outcomes. In IVW, the Wald ratio for each SNP was weighted by its inverse variance, and the effect estimates were meta-analyzed using random effects.

Sensitivity Analysis {#S2.SS5}
--------------------

Sensitivity analysis was used to test the disproportionate effects of variants and the pleiotropy in the MR analysis ([@B27]). A series of sensitivity analyses were conducted to test the robustness of the conventional MR results.

Multivariable IVW, which included the DBP, SBP, HDL-C, and LDL-C as covariates, was carried out in accordance with the method proposed by [@B31] that was used to account for possible horizontal pleiotropy arising from the association of the instrument with these variables.

The MR--Egger regression and weighted median method are two pleiotropy-robust MR methods that are used to estimate consistent causal effects against unknown directional pleiotropy under the InSIDE assumptions ([@B7]). In the MR--Egger regression method, the regression line fitted to the data is not constrained to pass through the origin, and the intercept represents the horizontal pleiotropic effect that may bias the IVW estimate, whereas the slope represents pleiotropy-corrected causal estimates. The weighted median method has considerable robustness to individual genetics with strongly outlying causal estimates and could provide a consistent causal estimate when the valid IVs exceed 50%.

The MR--PRESSO method was used to identify potential outliers in the conventional MR testing, and provided a robust estimate with outlier correction. Moreover, testing of significant distortion in the IVW causal estimate before and after MR--PRESSO correction, was undertaken and served as a sensitivity analysis.

The leave-one-out sensitivity analysis was conducted to ascertain whether the association was being disproportionately influenced by a single SNP. In this analysis, the random-effects IVW was repeated by leaving out each SNP in turn, and the overall analysis including all SNPs was used for the comparison. The variation of the results from before and after the removal of each SNP reflects the sensitivity of this SNP.

Results {#S3}
=======

Genetic IVs {#S3.SS1}
-----------

A total of 546, 356, and 330 IVs were identified for BMI, WHR, and WHRadjBMI, respectively. Some IVs were absent in the outcome data; however, the *F* statistics for BMI-IVs (86.250--89.078), WHR-IVs (67.502--67.991), and WHRadjBMI-IVs (90.758--96.860) that were used for MR were more than 10, which indicated that the weak instrument bias was negligible. Detailed information of IVs used in this study are shown in [Supplementary Table S1](#TS1){ref-type="supplementary-material"}.

Horizontal Pleiotropy and Heterogeneity Analysis {#S3.SS2}
------------------------------------------------

The MR--Egger regression intercepts obtained in this study ([Table 2](#T2){ref-type="table"}) showed that horizontal pleiotropy (*P* = 0.029) was only found in the MR with WHRadjBMI as exposure and fasting insulin as the outcome. Heterogeneity ([Table 2](#T2){ref-type="table"}) was observed between IVs; therefore, the random-effect IVW method was used in the subsequent stages of the research analysis. The MR--PRESSO test showed that horizontal pleiotropy was found in all IVW analyses in this study, and the horizontal pleiotropic outliers were identified and removed ([Supplementary Table S2](#TS2){ref-type="supplementary-material"}). After the removal of these outliers, the *F*-statistics of BMI-IVs (85.704--89.033), WHR-IVs (62.240--67.991), and WHRadjBMI-IVs (84.668--96.860) continued to remain well powered to estimate the causal effect of the exposure on the outcome.

###### 

Heterogeneity and horizontal pleiotropy analysis.

  Exposure        Outcome           Heterogeneity   Horizontal pleiotropy                                                           
  --------------- ----------------- --------------- ----------------------- ---------- ---------- ---------- ---------------------- -------
  **BMI**                                                                                                                           
                  T2DM              2867.057        445                     \< 0.001   2885.029   \< 0.001   −0.001 (0.994,1.005)   0.837
                  HOMA-IR           510.260         446                     0.019      512.445    0.023      0 (0.998,1.001)        0.430
                  HbA1c             654.863         445                     \< 0.001   658.515    \< 0.001   0 (0.999,1)            0.714
                  Fasting insulin   624.170         448                     \< 0.001   626.889    \< 0.001   0 (0.999,1.001)        0.842
                  Fasting glucose   619.187         448                     \< 0.001   622.082    \< 0.001   0 (0.999,1.001)        0.838
  **WHR**                                                                                                                           
                  T2DM              1718.377        275                     \< 0.001   1739.466   \< 0.001   0.008 (1,1.017)        0.055
                  HOMA-IR           368.360         277                     \< 0.001   371.364    \< 0.001   0 (0.998,1.002)        0.729
                  HbA1c             413.286         279                     \< 0.001   416.611    \< 0.001   0 (0.999,1.001)        0.695
                  Fasting insulin   431.511         280                     \< 0.001   435.262    \< 0.001   0 (0.998,1.002)        0.853
                  Fasting glucose   358.324         280                     0.001      361.045    0.001      0 (0.998,1.002)        0.935
  **WHRadjBMI**                                                                                                                     
                  T2DM              1590.053        236                     \< 0.001   1609.124   \< 0.001   0.003 (0.995,1.011)    0.455
                  HOMA-IR           290.496         237                     0.010      293.251    0.011      −0.001 (0.997,1.001)   0.175
                  HbA1c             383.587         238                     \< 0.001   387.452    \< 0.001   0 (0.999,1)            0.355
                  Fasting insulin   362.009         239                     \< 0.001   365.491    \< 0.001   −0.002 (0.997,1)       0.029
                  Fasting glucose   276.448         239                     0.048      278.957    0.047      −0.001 (0.998,1.001)   0.319

WHR, waist-to-hip ratio; BMI, body mass index; WHRadjBMI, waist-to-hip ratio adjusted for body mass index; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; DBP, diastolic blood pressure; T2DM, Type 2 diabetes; SD, standard deviation; HOMA-IR, Homeostasis model assessment of insulin resistance; HbA1c, Hemoglobin A1c; Q,

Cochran's Q

test estimate; df,

Cochran's Q

test degrees of freedom; MR--egger, Mendelian randomization--Egger regression; MR--PRESSO, Mendelian randomization pleiotropy residual sum and outlier method; OR, odds ratio; CI, confidence interval.

Causal Effect of WHR, BMI, and WHRadjBMI on T2DM and Glycemic Traits {#S3.SS3}
--------------------------------------------------------------------

[Table 3](#T3){ref-type="table"} and [Figure 1](#F1){ref-type="fig"} show the causal effect estimates of WHR, BMI, and WHRadjBMI on T2DM and glycemic traits. The TSMR analysis by the IVW method showed a significant causal effect, wherein each SD of genetically higher BMI was associated with an increased T2DM risk \[OR: 2.741; 95% confidence interval (CI): 2.421--3.104\], higher fasting glucose \[1.073; 1.048--1.099\], higher fasting insulin \[1.202; 1.173--1.231\], higher HOMA-IR \[1.221; 1.187--1.255\], and higher HbA1c \[1.054; 1.04--1.068\]. Each SD of genetically higher WHR was associated with increased T2DM risk \[3.12; 2.653--3.668\], higher fasting glucose \[1.087; 1.054--1.12\], higher fasting insulin \[1.193; 1.153--1.234\], higher HOMA-IR \[1.203; 1.155--1.252\], and higher HbA1c \[1.075; 1.056--1.095\]. Each SD of genetically higher WHRadjBMI was associated with increased T2DM risk \[1.993; 1.704--2.33\], higher fasting glucose \[1.039; 1.012--1.067\], higher fasting insulin \[1.102; 1.068--1.136\], higher HOMA-IR \[1.127; 1.088--1.167\], and higher HbA1c \[1.061; 1.042--1.08\].

###### 

Mendelian randomization results.

                                                         BMI   WHR                  WHRadjBMI                                                                    
  --------------------- -------------------------------- ----- -------------------- ----------- ----- -------------------- ---------- ----- -------------------- ----------
  **T2DM**                                                                                                                                                       
                        IVW                              446   2.741(2.421,3.104)   6.12E-57    276   3.12(2.653,3.668)    3.87E-43   237   1.993(1.704,2.33)    5.59E-18
                        MR--PRESSO (Outlier-corrected)   433   3.064(2.871,3.271)   9.15E-123   254   3.543(3.164,3.968)   2.67E-60   211   2.117(1.908,2.35)    3.06E-32
                        Multivariable MR                 842   3.338(2.625,4.246)   1.47E-20    672   2.887(2.54,3.281)    3.66E-50   633   2.105(1.755,2.524)   8.57E-15
                        Weighted median                  446   2.835(2.576,3.12)    6.18E-101   276   2.769(2.43,3.156)    1.02E-52   237   1.983(1.764,2.229)   1.74E-30
                        MR--Egger                        446   2.829(2.042,3.918)   9.28E-10    276   1.894(1.109,3.234)   0.020      237   1.699(1.087,2.656)   0.0201
  **HOMA-IR**                                                                                                                                                    
                        IVW                              447   1.221(1.187,1.255)   6.69E-44    278   1.203(1.155,1.252)   4.03E-19   238   1.127(1.088,1.167)   3.69E-11
                        MR--PRESSO (Outlier-corrected)   446   1.223(1.19,1.258)    5.15E-38    278   NA                   NA         238   NA                   NA
                        Multivariable MR                 723   1.294(1.187,1.411)   1.29E-08    554   1.192(1.148,1.237)   1.28E-18   529   1.197(1.134,1.262)   1.61E-10
                        Weighted median                  447   1.214(1.161,1.27)    2.79E-17    278   1.18(1.114,1.251)    2.25E-08   238   1.128(1.07,1.188)    6.90E-06
                        MR--Egger                        447   1.255(1.165,1.352)   4.41E-09    278   1.175(1.024,1.348)   0.022      238   1.199(1.089,1.32)    2.72E-3
  **HbA1c**                                                                                                                                                      
                        IVW                              446   1.054(1.04,1.068)    4.99E-14    280   1.075(1.056,1.095)   1.13E-14   239   1.061(1.042,1.08)    3.85E-11
                        MR--PRESSO (Outlier-corrected)   441   1.05(1.036,1.064)    9.67E-13    278   1.075(1.056,1.094)   4.41E-14   235   1.054(1.037,1.072)   1.61E-09
                        Multivariable MR                 735   1.076(1.031,1.123)   8.11E-3     569   1.074(1.055,1.093)   5.04E-14   543   1.065(1.038,1.094)   3.79E-06
                        Weighted median                  446   1.06(1.04,1.081)     3.83E-09    280   1.07(1.044,1.096)    4.60E-08   239   1.059(1.034,1.085)   2.08E-06
                        MR--Egger                        446   1.06(1.024,1.099)    0.001       280   1.062(0.998,1.131)   0.058      239   1.084(1.033,1.137)   0.001
  **Fasting insulin**                                                                                                                                            
                        IVW                              449   1.202(1.173,1.231)   4.73E-50    281   1.193(1.153,1.234)   2.28E-24   240   1.102(1.068,1.136)   6.37E-10
                        MR--PRESSO (Outlier-corrected)   446   1.198(1.17,1.226)    4.55E-42    280   1.201(1.162,1.241)   3.45E-23   237   1.108(1.077,1.141)   2.80E-11
                        Multivariable MR                 742   1.298(1.204,1.4)     6.62E-11    574   1.184(1.147,1.223)   5.81E-23   548   1.179(1.125,1.235)   2.18E-11
                        Weighted median                  449   1.213(1.168,1.26)    1.54E-23    281   1.187(1.136,1.24)    1.41E-14   240   1.129(1.083,1.177)   1.03E-08
                        MR--Egger                        449   1.209(1.134,1.289)   1.06E-08    281   1.18(1.052,1.324)    0.005      240   1.2(1.105,1.304)     2.29E-05
  **Fasting glucose**                                                                                                                                            
                        IVW                              449   1.073(1.048,1.099)   4.53E-09    281   1.087(1.054,1.12)    8.78E-08   240   1.039(1.012,1.067)   0.004
                        MR--PRESSO (Outlier-corrected)   446   1.083(1.059,1.107)   7.61E-12    278   1.098(1.067,1.13)    7.19E-10   239   1.044(1.017,1.072)   0.001
                        Multivariable MR                 742   1.025(0.947,1.109)   0.546       574   1.067(1.034,1.102)   8.18E-05   548   1.019(0.971,1.069)   0.443
                        Weighted median                  449   1.077(1.041,1.114)   1.88E-05    281   1.092(1.048,1.138)   2.60E-05   240   1.058(1.017,1.101)   0.005
                        MR--Egger                        449   1.067(1.002,1.136)   0.043       281   1.091(0.984,1.209)   0.098      240   1.075(1.001,1.155)   0.049

WHR, waist-to-hip ratio; BMI, body mass index; WHRadjBMI, waist-to-hip ratio adjusted for body mass index; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; DBP, diastolic blood pressure; T2DM, type 2 diabetes; SD, standard deviation; HOMA-IR, homeostasis model assessment of insulin resistance; HbA1c, hemoglobin A1c; nSNP, numbers of the SNPs (instrumental variable) used in Mendelian randomization; IVW, inverse-variance weighted; MR--egger, Mendelian randomization--Egger regression; MR--PRESSO, Mendelian randomization pleiotropy residual sum and outlier method; OR, odds ratio; CI, confidence interval.

![Scatterplot and causal effect of body mass index (BMI), waist-to-hip ratio (WHR), and WHR adjusted for BMI (WHRadjBMI) on type 2 diabetes mellitus (T2DM) and glycemic traits including HOMA-IR, fasting insulin, fasting glucose and glycate hemoglobin (HbA1c). **(A)** Causal effect of WHRadjBMI on T2DM, **(B)** Causal effect of WHRadjBMI on HOMA-IR, **(C)** Causal effect of WHRadjBMI on fasting glucose, **(D)** Causal effect of WHRadjBMI on fasting insulin, **(E)** Causal effect of WHRadjBMI on HbA1c, **(F)** Causal effect of WHR on T2DM, **(G)** Causal effect of WHR on HOMA-IR, **(H)** Causal effect of WHR on fasting glucose, **(I)** Causal effect of WHR on fasting insulin, **(J)** Causal effect of WHR on HbA1c, **(K)** Causal effect of BMI on T2DM, **(L)** Causal effect of BMI on HOMA-IR, **(M)** Causal effect of BMI on fasting glucose, **(N)** Causal effect of BMI on fasting insulin, and **(O)** Causal effect of BMI on HbA1c. The *x*-axis presents the single nucleotide polymorphism (SNP) effect on exposure, and the *y*-axis presents the SNP effect on outcome. The light blue, dark blue and green regression line represents the inverse-variance weighted (IVW), Mendelian randomization (MR)--Egger, and weighted median estimate, respectively.](fgene-11-00603-g001){#F1}

Sensitivity Analysis {#S3.SS4}
--------------------

In the leave-one-out sensitivity analysis, no single SNP strongly or reversely drove the overall effect of exposure on outcome in the IVW ([Supplementary Figure S1](#FS1){ref-type="supplementary-material"}). Consistent results were observed in the IVW after the MR--PRESSO correction, MR--Egger regression, and the weighted median method, with the exception of the causal estimates of WHR on HbA1c (*P* = 0.058) and fasting glucose (*P* = 0.098) in the MR--Egger regression. The MR--Egger regression could obtain pleiotropy-corrected causal estimates, although this method had less statistical power than an equivalent IVW method, and the CIs were wider and included the null value ([@B6]; [@B41]). Because the intercept of the MR--Egger regression indicates that there was no horizontal pleiotropy in the MR--Egger regression between WHR and both HbA1c (*P* = 0.695) and fasting glucose (*P* = 0.935), the causal estimate was more convincing in the IVW. In the multivariable IVW (DBP, SBP, HDL-C, and LDL-C as covariates), BMI (*P* = 0.546) and WHRadjBMI (*P* = 0.443) were not causally associated with fasting glucose, whereas other multivariable IVW results persisted with that in the univariable IVW.

Taken together, the causal effect estimates of BMI and WHRadjBMI on fasting glucose in conventional MR might be biased by the horizontal pleiotropy of SBP, DBP, HDL-C, and LDL-C, while no significant bias was found in other causal effect estimates despite the existence of horizontal pleiotropy and heterogeneity.

Discussion {#S4}
==========

Numerous observational studies indicated that obesity was strongly associated with T2DM risk and glycemic traits ([@B24]), however, a causal effect cannot be ascertained from these studies due to residual confounding or reverse causality. This present study utilized a TSMR design that was applied to the summary-level data from a large-scale genome-wide association study to address the potential causal role of overall obesity (measured by BMI) and abdominal obesity (measure by WHRadjBMI) on the risk of T2DM and glycemic traits. The well-powered conventional MR (random-effect IVW method) confirmed that genetic predisposition to higher BMI, WHR, and WHRadjBMI are causally associated with higher fasting glucose, fasting insulin, HOMA-IR, HbA1c, and increased risk of T2DM in the European population.

However, heterogeneity and horizontal pleiotropy was found in the conventional MR analysis, a series of sensitivity analyses that included the multivariable MR (DBP, SBP, HDL-C, and LDL-C as covariates), MR--Egger regression, weighted median method, MR--PRESSO method, and leave-one-out analysis to test the robustness of the conventional MR results. The causal effect of BMI and WHRadjBMI on T2DM risk, HbA1c, fasting insulin, and HOMA-IR in the conventional MR were consistent with that in all the sensitivity analyses, which suggested that the causal estimate was robust and unbiased.

Each SD of genetically higher BMI \[2.741; 2.421--3.104\] and WHRadjBMI \[1.993; 1.704--2.33\] was associated with increased T2DM risk. Human epidemiologic studies have considered obesity to be a major risk factor of T2DM, and the substantial increase in the incidence of obesity contributes to the current T2DM epidemic ([@B34]). Using the MR method in the European descendants, Emdin et al. confirmed that a 1 SD genetic increase in WHRadjBMI was associated with a higher risk of T2DM \[1.77; 1.57--2.00\] ([@B14]), and Dale et al. revealed that each SD higher BMI was associated with increased T2DM risk \[1.98; 1.41--2.78\] ([@B10]). The results of this study are in agreement with those of previous observational studies ([@B24]; [@B34]) and MR studies ([@B10]; [@B14]) which suggested that both overall and abdominal obesity play a causal role on T2DM risk in the European population. In addition, our MR studies suggested that the causal effect of overall obesity on T2DM risk was greater than that of abdominal obesity. Moreover, both BMI \[1.054; 1.04--1.068\] and WHRadjBMI \[1.061; 1.042--1.08\] were found to have a causal effect on HbA1c, which suggested that overall and abdominal obesity have a similar but small causal effect on the HbA1c.

Insulin resistance refers to a decreased physiological response of peripheral tissues to insulin action, which implies an impaired effect of insulin in lowering the blood glucose ([@B15]). This serves as the key mechanism and a major global driver of the T2DM condition ([@B33]; [@B9]). The accumulation of body fat and abdominal body fat are risk factors for increased insulin resistance ([@B21]; [@B16]), and high BMI and WHR were found to be positively correlated with insulin resistance in observational epidemiological studies ([@B16]; [@B5]; [@B23]). Wang et al. reported that higher BMI was causally correlated with increased Stumvoll first- and second-phase insulin secretion and HOMA-IR, whereas no causal relationship between WHR and HOMA-IR was found in a conventional MR study in the Chinese Han population ([@B40]). In Europeans, a previous MR study found that higher WHRadjBMI was causally associated with higher fasting insulin levels ([@B14]). The present MR study provides a similar conclusion with regard to the European population, each SD of genetically higher WHRadjBMI \[1.102; 1.068--1.136\] and BMI \[1.202; 1.173--1.231\] was found to play a positive causal effect on higher fasting insulin. Furthermore, each SD of genetically higher BMI \[1.221; 1.187--1.255\] and WHRadjBMI \[1.127; 1.088--1.167\] was causally associated with the HOMA-IR. These results suggested that higher overall and abdominal obesity serve as causal risk factors of fasting insulin and insulin resistance in the European population. The findings of the present study are supported by experimental studies as well. Obesity could stimulate the formation of lipid metabolites, hormones, and cytokines, which involves changes in the insulin signaling pathway and the accelerated progression of insulin resistance ([@B28]; [@B3]). Moreover, the causal effect of overall obesity on fasting insulin and insulin resistance is slightly greater than that of abdominal obesity. Thus, we highlighted that both mass and distribution of body fat play a causal role on insulin resistance and T2DM risk. This indicates that the development of therapies to modify the mass and distribution of body fat to reduce overall and abdominal obesity might contribute to the prevention and alleviation of T2DM and insulin resistance-related diseases.

Furthermore, although higher BMI and WHRadjBMI was found to be causally associated with higher fasting glucose in our conventional MR in the European population, no statistical significance was found between BMI and fasting glucose (*P* = 0.546) or with WHRadjBMI and fasting glucose (*P* = 0.443) in the multivariable MR (DBP, SBP, HDL-C, and LDL-C as covariates). The casual estimates of BMI and WHRadjBMI on fasting glucose in conventional MR might be biased by the horizontal pleiotropy of DBP, SBP, HDL-C, and LDL-C. These negative results warrant further investigation.

Through a comparison of the causal estimates of BMI and WHRadjBMI on glycemic traits (fasting glucose, fasting insulin, HOMA-IR, and HbA1c), this study further emphasizes that overall and abdominal obesity might increase the T2DM risk mainly via elevation of insulin resistance.

In conclusion, overall and abdominal obesity have a causal effect on the T2DM risk and insulin resistance, and overall obesity may have stronger effects, whereas they may have no causal effect on the fasting glucose. These results suggest that individuals can substantially reduce their insulin resistance and T2DM risk through reduction of body fat mass and modification of body fat distribution.
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